
The randomized clinical trial — conducted by researchers from the U.S., Israel, Canada and the Netherlands — involved 2,221 people and compared the ridaforolimus-eluting stent from Medinol with the zotarolimus-eluting stent from Medtronic.
Approved by FDA in 2017, the first commercial implants of EluNIR took place in the U.S. in early 2018. The Cordis business at Cardinal Health (NYSE:CAH) is the stent’s U.S. distributor.
Get the full story on our sister site Drug Delivery Business News.